VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Stock Comparison

ChemoMetec A/S vs Sanofi

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

ChemoMetec A/S

CHEMM · Nasdaq Copenhagen A/S

Market cap (USD)
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
Industry
CountryDK
Data as of2026-04-24
Moat score
67/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into ChemoMetec A/S's moat claims, evidence, and risks.

View CHEMM analysis

Sanofi

SAN · Euronext Paris

Market cap (USD)$113.7B
Gross margin (TTM)71.7%
Operating margin (TTM)25.4%
Net margin (TTM)18.2%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryFR
Data as of2025-12-30
Moat score
74/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Sanofi's moat claims, evidence, and risks.

View SAN analysis

Comparison highlights

  • Moat score gap: Sanofi leads (74 / 100 vs 67 / 100 for ChemoMetec A/S).
  • Segment focus: ChemoMetec A/S has 2 segments (94.8% in Life science research, cell and gene therapy, and bioprocessing); Sanofi has 3 segments (79.8% in Pharma (Prescription Medicines)).
  • Moat breadth: ChemoMetec A/S has 4 moat types across 2 domains; Sanofi has 5 across 3.

Primary market context

ChemoMetec A/S

Life science research, cell and gene therapy, and bioprocessing

Market

Global cell counting and analysis instruments for LCB workflows

Geography

Global, skewed to USA/Canada and Europe

Customer

Pharmaceutical, biotech, cell and gene therapy, bioprocessing, and research labs

Role

OEM instrument, consumables, software, and service provider

Revenue share

94.8%

Sanofi

Pharma (Prescription Medicines)

Market

Branded prescription pharmaceuticals (immunology, rare disease, neurology, oncology, general medicines)

Geography

Global

Customer

Patients via payers/providers and channel partners (wholesalers, pharmacies, hospitals)

Role

Research-based drug developer, manufacturer, and marketer

Revenue share

79.8%

Side-by-side metrics

ChemoMetec A/S
Sanofi
Ticker / Exchange
CHEMM - Nasdaq Copenhagen A/S
SAN - Euronext Paris
Market cap (USD)
n/a
$113.7B
Gross margin (TTM)
n/a
71.7%
Operating margin (TTM)
n/a
25.4%
Net margin (TTM)
n/a
18.2%
Sector
Healthcare
Healthcare
Industry
n/a
Drug Manufacturers - General
HQ country
DK
FR
Primary segment
Life science research, cell and gene therapy, and bioprocessing
Pharma (Prescription Medicines)
Market structure
Oligopoly
Oligopoly
Market share
15%-25% (estimated)
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
67 / 100
74 / 100
Moat domains
Demand, Network
Legal, Supply, Demand
Last update
2026-04-24
2025-12-30

Moat coverage

Shared moat types

Brand Trust

ChemoMetec A/S strengths

Installed Base ConsumablesDesign In QualificationInteroperability Hub

Sanofi strengths

Regulated Standards PipeIP Choke PointLearning Curve YieldDistribution Control

Segment mix

ChemoMetec A/S segments

Full profile >

Life science research, cell and gene therapy, and bioprocessing

Oligopoly

94.8%

Production control and quality control of animal semen, beer and milk

Quasi-Monopoly

5.2%

Sanofi segments

Full profile >

Pharma (Prescription Medicines)

Oligopoly

79.8%

Vaccines

Oligopoly

20.2%

Opella (Consumer Healthcare - Sanofi minority stake)

Competitive

n/a

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.